TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Cellipont Bioservices and Wugen Forge Deal for Clinical Production of Off-the-Shelf CAR-T Cellular Therapies

Friday, March 15, 2024

Cellipont Bioservices and Wugen, Inc. have recently announced a collaborative agreement aimed at advancing cancer treatment through the manufacturing of CAR-T cell therapies. As per the agreement, Cellipont Bioservices will utilize its modern 76,000 sq. ft. manufacturing facility to provide technology transfer and production services for Wugen's allogeneic CAR-T cell therapies.

Wugen specializes in developing off-the-shelf memory natural killer (NK) and CAR-T cell therapies for various hematological and solid tumor malignancies. These investigational therapies, sourced from healthy donors and engineered to enhance cancer cell elimination, hold promise for patients with solid tumors, acute myeloid leukemia (AML), and T-cell malignancies.

Kumar Srinivasan, Ph.D., MBA, president and CEO of Wugen, expressed enthusiasm about the collaboration, highlighting its potential to bring innovative CAR-T cell therapies to patients in need. Edwin Beale, CCO of Cellipont, echoed this sentiment, emphasizing the partnership's role in driving innovation and expediting the development of life-saving treatments globally.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit